RNA · Company research
Atrium Therapeutics, Inc. Common Stock (RNA): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 7.99 | $143,690,400 | -120209600.0 | — | — | — | 6.2412456380582181 | 0.66964805010812019984 | — |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.